708274-10-6

Usage

Chemical Structure

A complex structure consisting of a spiro ring and a thiazole ring.

Physical Appearance

White to off-white powder.

Solubility

Insoluble in water, soluble in organic solvents.

Pharmaceutical industry

As a building block for the synthesis of biologically active molecules.

Organic synthesis

Due to its unique structural properties.

Material science

Potential uses in the field, but further research is needed.

Research Status

Further research and testing are necessary to fully understand the potential uses and properties of this chemical compound.

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 79265-30-8 2-(trimethylsilyl)thiazole 
• 1228652-56-9 8-(2-trimethylsilanyl-thiazol-5-yl)-1,4-dioxa-spiro[4.5]decan-8-ol 
• 1228653-00-6 C₁₇H₂₉NO₃SSi 

Downstream Products

• 857650-94-3 4-hydroxy-4-[2-(morpholin-4-ylcarbonyl)-1,3-thiazol-5-yl]cyclohexanone 
• 870483-69-5 4-hydroxy-4-thiazol-5-yl-cyclohexanone 

Relevant academic research and scientific papers

Discovery of a 4-Azetidinyl-1-thiazoyl-cyclohexane CCR2 antagonist as a development candidate

We have discovered a novel series of 4-Azetidinyl-1-Aryl-cyclohexanes as CCR2 antagonists. Divergent SAR studies on hCCR2 and hERG activities led to the discovery of compound 8d, which displayed good hCCR2 binding affinity (IC 50, 37 nM) and po

A METHOD OF TREATING LIVER FIBROSIS

The present invention relates to a method of treating hepatis C and/or liver fibroisis with 3-cycloalkylaminopyrrolidine derivatives of the present invention

CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). Wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, and R4 are as defined in the specification. The invention also comprises pharmaceutical compositions comprising the compounds of formula (I) and methods of preventing, treating or ameliorating a CCR2 mediated syndrome, disorder or disease, for example, type II diabetes, obesity or asthma, by administering the compounds of formula (I).

3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors

The present invention relates to 3-cycloalkylaminopyrrolidine derivatives of the formula I: (wherein R1, R2, R3, R4, R5, R6, R7, X, Y and Z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.

3-(4-Heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors

The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or act